Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pacific Biosciences of California, Inc. - Common Stock
(NQ:
PACB
)
1.220
-0.030 (-2.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pacific Biosciences of California, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
5 Top Stocks Cathie Wood Bought This Week
↗
August 05, 2022
Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week.
Via
InvestorPlace
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
↗
August 05, 2022
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
Via
Benzinga
Small Cap Biotech Stocks Are Trending Well
↗
July 18, 2022
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.
Via
Talk Markets
Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
↗
May 16, 2022
Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over...
Via
Benzinga
Pacific Biosciences Clocks 14% Jump In Q1 Revenues
↗
May 05, 2022
Via
Benzinga
Pacific Biosciences Shares Fall As Q4 Earnings Miss Estimates
↗
February 16, 2022
Pacific Biosciences of California Inc (NASDAQ: PACB) reported
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
January 18, 2022
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...
Via
Benzinga
Recap: Pacific Biosciences Q1 Earnings
↗
May 04, 2022
Pacific Biosciences (NASDAQ:PACB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 16, 2022
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...
Via
Talk Markets
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 15, 2022
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.
Via
Benzinga
How do Biotechnology Funds and ETFs Perform Over Five Years?
↗
March 21, 2022
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Thursday
↗
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
↗
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
↗
February 16, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) rose 41.8% to $1.90 in pre-market trading after the company announced it entered into an amended and restated collaboration...
Via
Benzinga
Recap: Pacific Biosciences Q4 Earnings
↗
February 15, 2022
Pacific Biosciences (NASDAQ:PACB) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
↗
February 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
↗
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
Bionano Is Not the Genomics Stock To Bet On
↗
February 04, 2022
Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.
Via
InvestorPlace
Earnings Scheduled For February 15, 2022
↗
February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
January 19, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...
Via
Benzinga
48 Biggest Movers From Yesterday
↗
January 12, 2022
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT...
Via
Benzinga
Mid-Afternoon Market Update: Dow Rises 150 Points; Accolade Shares Spike Higher
↗
January 11, 2022
Toward the end of trading Tuesday, the Dow traded up 0.43% to 36,224.50 while the NASDAQ rose 1.33% to 15,142.08. The S&P also rose, gaining, 0.75% to 4,705.23. The U.S. has...
Via
Benzinga
Illumina Jumps As Gene Sequencing Demand Drives Stronger Outlook
↗
January 11, 2022
Piper says Pacific Bio has a new competitor in Illumina amid plans to launch what looks like a consumable allowing long-read sequencing on its analyzers.
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
January 11, 2022
Gainers Nutriband (NASDAQ:NTRB) stock moved upwards by 20.7% to $7.29 during Tuesday's regular session. Trading volume for Nutriband's stock is 6.4 million as of...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 3.5%; Pacific Biosciences of California Shares Fall
↗
January 11, 2022
Midway through trading Tuesday, the Dow traded down 0.50% to 35,889.26 while the NASDAQ fell 0.16% to 14,919.61. The S&P also fell, dropping, 0.39% to 4,652.01. The U.S. has...
Via
Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
↗
January 11, 2022
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year....
Via
Benzinga
52 Weeks High And Low Article
↗
January 11, 2022
Stocks that Broke Yearly Lows Tuesday Morning During Tuesday's morning trading, 87 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Highs And Lows: 10x...
Via
Benzinga
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
↗
January 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
